SCHEMBL4923595

SCHEMBL4923595

Cc1nc(C(=O)NC2CCOCC2)cc2c(Nc3cccc4c3CCO4)c(C(N)=O)cnc12

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PDE4B Q07343 3/20 0.53
KCNH2 Q12809 5/20 0.38
ATM Q13315 3/20 0.36
ATR Q13535 1/20 0.36
CYP3A4 P08684 2/20 0.36
CYP2C9 P11712 2/20 0.36
BRD4 O60885 2/20 0.36
BRD2 P25440 2/20 0.36
BRD3 Q15059 2/20 0.36
CYP2C19 P33261 1/20 0.36
CNR2 P34972 3/20 0.36
JAK2 O60674 1/20 0.36
JAK1 P23458 1/20 0.36
TYK2 P29597 1/20 0.36
JAK3 P52333 1/20 0.36
MTNR1B P49286 1/20 0.35
CSF1R P07333 1/20 0.35
CHRM1 P11229 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL4926823 0.88 PDE4B (0.46) PDE4BKCNH2CYP3A4CYP2C9BRD4
SCHEMBL4928534 0.87 PDE4B (0.59) PDE4BCYP3A4CYP2C9BRD4BRD2
SCHEMBL5763692 0.87 PDE4B (0.54) PDE4BKCNH2ATMATRCNR2
SCHEMBL4924230 0.86 PDE4B (0.57) PDE4BCYP3A4CYP2C9BRD4BRD2
SCHEMBL4928496 0.85 PDE4B (0.54) PDE4BKCNH2CYP3A4CYP2C9CNR2
Trifluoroacetic Acid SCHEMBL4924249 0.85 PDE4B (0.48) PDE4BCYP3A4CYP2C9CYP2C19CNR2
SCHEMBL14168749 0.85 PDE4B (0.58) PDE4BCYP3A4CYP2C9BRD4BRD2
SCHEMBL4299675 0.83 PDE4B (0.60) PDE4BKCNH2CYP3A4CYP2C9BRD4
SCHEMBL4928787 0.83 PDE4B (0.55) PDE4BCYP3A4CYP2C9BRD4BRD2
Trifluoroacetic Acid SCHEMBL4929251 0.82 PDE4B (0.48) PDE4BKCNH2ATMCYP3A4CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080146563-A1 1,7-Naphthyridines as Pde4 Inhibitors GLAXO GROUP LIMITED 2008-06-19 US claimed
US-20080146563-A1 1,7-Naphthyridines as Pde4 Inhibitors GLAXO GROUP LIMITED 2008-06-19 US disclosed
US-20080146563-A1 1,7-Naphthyridines as Pde4 Inhibitors GLAXO GROUP LIMITED 2008-06-19 US disclosed
WO-2006097340-A1 1,7-NAPHTHYRIDINES AS PDE4 INHIBITORS GLAXO GROUP LIMITED (GB) 2006-09-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080146563-A1 1,7-Naphthyridines as Pde4 Inhibitors PDE4A, PDE3B, PDE4B PDE4B 3/4885KCNH2 594/4885ATM 2742/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.